Duality Biotherapeutics Inc

Duality Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company that discovers and develops antibody-drug conjugate (ADC) therapeutics for cancer, autoimmune diseases, and other conditions in China and internationally. Its pipeline includes DB-1303/BNT323, a HER2 ADC candidate targeting cancers such as endometrial cancer and breast cancer, and DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers including small-cell lung cancer, castration-resistant prostate cancer, esophageal squamous cell carcinoma, and head and neck squamous cell carcinoma, along with other clinical-stage ADCs. The company has strategic partnerships with BioNTech SE to develop therapies intended to complement or replace chemotherapy, with BeOne to develop and commercialize DB-1312, an in-house discovered B7-H4-targeted ADC, and with Genentech, Inc. to develop antibody-drug conjugates. Incorporated in 2019, it is headquartered in Shanghai, China.